Share Email Print

Proceedings Paper

Current therapy for laser-induced retinal injury: overview of clinical and experimental approaches
Author(s): Steven T. Schuschereba; David K. Scales
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Adequate treatment strategies do not exist for retinal laser injuries. To gain a better understanding of available treatments, data form a variety of human laser accident cases and relevant experimental work was evaluated. Most laser eye injury cases are not attended by an ophthalmologist for several hours to days after injury and most patients are not treated.Of the few cases receiving treatment; only the FDA approved glucocortocoids are available for use. Their use, however, is still controversial. Experimental animal work during the acute phase of injury indicates that productive efforts have targeted neuroprotection, inflammation, ischemia- reperfusion, and lipid peroxidation. Late stage issues for treatment are scarring, retinal hole persistence and expansion, and traction. In summary, treatments for acute and late phase injury are currently inadequate. Preserving existing neural elements should be the top priority in these injuries. We recommend that relevant treatments begin immediately after injury. Other approaches are necessary to target early and late phase secondary damage events that are entrenched.

Paper Details

Date Published: 2 May 1997
PDF: 18 pages
Proc. SPIE 2974, Laser and Noncoherent Ocular Effects: Epidemiology, Prevention, and Treatment, (2 May 1997); doi: 10.1117/12.275240
Show Author Affiliations
Steven T. Schuschereba, Walter Reed Army Institute of Research (United States)
David K. Scales, Wilford Hall Medical Ctr. (United States)

Published in SPIE Proceedings Vol. 2974:
Laser and Noncoherent Ocular Effects: Epidemiology, Prevention, and Treatment
Bruce E. Stuck; Michael Belkin, Editor(s)

© SPIE. Terms of Use
Back to Top